1 October 2026

Cardiogeni PLC
(“Cardiogeni” or the “Company”)

Annual report update and temporary suspension from trading

Cardiogeni (AQSE: CGNI), a UK clinical stage biotechnology company founded by 2007 Nobel
Laureate Sir Martin Evans to develop and commercialise novel heart regeneration medicines,
announces that the publication of its audited annual accounts for the year ended 31 March
2026 will be delayed beyond 30 September 2026. This is due to auditor resourcing constraints,
which led to the appointment of a new auditor, HaysMac LLP, later in the process than usual.
As a result, trading in the Company’s shares on the Aquis Stock Exchange Growth Market will
be suspended with effect from 7.30 a.m. today, pending publication of the audited annual
accounts.

The audit is progressing well and the Company expects to publish its audited annual accounts
in the second half of October 2026, at which point it will seek restoration of trading, and will
provide further updates as appropriate.

Contacts

Cardiogeni PLC
Dr Darrin M Disley, Executive Chairman
Ajan Reginald, Executive Officer
Via First Sentinel

First Sentinel Corporate Finance Limited, Corporate Adviser
Brian Stockbridge
Gabrielle Cordeiro
+44 020 3855 5551

SP Angel Corporate Finance LLP, Corporate Broker
David Hignell
Vadim Alexandre
Devik Mehta
+44 20 3470 0470